Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02666378

Enrollment

Registered

2016-01-28

Start date

2018-09-10

Completion date

2024-07-10

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.

Detailed description

One of the side effects observed in breast cancer patients receiving anthracycline-based treatment is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body. This complication can lead to the following symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a reduced capacity to carry out day-to-day activities. This research study is focused on identifying the early signs of such heart complications using CMR, which may allow preventative treatment options to be made available in future.

Interventions

OTHERCardiac Magnetic Resonance Imaging (CMR)

Subjects will be recruited for observational cardiac magnetic resonance imaging.

OTHEREchocardiogram (ECHO)

Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Have histologic diagnosis of breast carcinoma * Scheduled to receive standard clinical therapy designed by their treating oncologist * Patients should receive anthracycline as part of the recommended treatment * Able to give informed consent.

Exclusion criteria

* Contraindication to contrast CMR including eGFR \<30 mls/min/1.73m2 * Uncontrolled serious concurrent illness * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame	Description
Cardiotoxicity	1 year after completion of treatment	Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026